(Q50545459)

English

Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database

scientific article published in March 2007

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17476624

Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17476624

0 references

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

author name string

Ostergaard M

1

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17476624

Unkerskov J

2

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17476624

Linde L

3

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17476624

Krogh NS

4

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17476624

Ravn T

5

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17476624

Ringsdal VS

6

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17476624

Petri A

7

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17476624

Andersen LS

8

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17476624

Tarp U

9

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17476624

Hansen A

10

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17476624

Hjardem E

11

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17476624

Hetland ML

12

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17476624

publication date

1 March 2007

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17476624

Scandinavian Journal of Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17476624

36

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17476624

2

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17476624

151-154

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17476624

Clinical responses to tumor necrosis factor alpha antagonists do not show a bimodal distribution: data from the Stockholm tumor necrosis factor alpha followup registry

1 reference

https://api.crossref.org/works/10.1080%2F03009740601089267

21 January 2018

Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious

1 reference

https://api.crossref.org/works/10.1080%2F03009740601089267

21 January 2018

Treatment continuation in patients receiving biological agents or conventional DMARD therapy

1 reference

https://api.crossref.org/works/10.1080%2F03009740601089267

21 January 2018

Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.

1 reference

https://api.crossref.org/works/10.1080%2F03009740601089267

21 January 2018

Routine database registration of biological therapy increases the reporting of adverse events twentyfold in clinical practice. First results from the Danish Database (DANBIO).

1 reference

https://api.crossref.org/works/10.1080%2F03009740601089267

21 January 2018

Guidelines for the management of rheumatoid arthritis: 2002 Update

1 reference

https://api.crossref.org/works/10.1080%2F03009740601089267

21 January 2018

Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept

1 reference

https://api.crossref.org/works/10.1080%2F03009740601089267

21 January 2018

Identifiers

10.1080/03009740601089267

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17476624

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17476624

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50545459&oldid=2252547037"